𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cellular oncogenes and suppressor genes as prognostic markers in cancer

✍ Scribed by M.J. Duffy

Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
984 KB
Volume
26
Category
Article
ISSN
0009-9120

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Expression of the putative tumor suppres
Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer
✍ FranΓ§oise RΓ©villion; Carole Puech; Fanja Rabenoelina; Dany Chalbos; Jean-Philipp πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 139 KB πŸ‘ 1 views

## Abstract Although it is well established that some protein tyrosine kinases have a prognostic value in breast cancer, the involvement of protein tyrosine phosphatases (PTPs) is poorly substantiated for breast tumors. Three of these enzymes (PTP‐gamma, LAR, and PTPL1) are already known to be regu

Chapter III. 1. Mutations in human breas
Chapter III. 1. Mutations in human breast cancer cells: Dominantly-acting oncogenes and tumor suppressor genes suggest strategies for targeted interference
✍ Bernd Groner; Nancy E. Hynes πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 French βš– 745 KB

The etiology of breast cancer has been linked in the past to a number of "macroscopic" events which include the family history of cancer, benign breast disease, reproductive history, exposure to estrogens and diet. The disease itself has been analyzed at different stages and premalignant initiation

Serum cytochrome c indicates in vivo apo
Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy
✍ Katarzyna Barczyk; Michael Kreuter; Juliusz Pryjma; Evan P. Booy; Subbareddy Mad πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 248 KB

## Abstract Despite significant progress in cancer therapy, the outcome of the treatment is often unfavorable. Better treatment monitoring would not only allow an individual more effective, patient‐adjusted therapy, but also it would eliminate some of the side effects. Using a cytochrome c ELISA th